Submission of Investor Presentation for the quarter ended on September 30, 2026

SEPL/SE/October/26-27 29th October 2026 The General Manager, The Manager, Corporate Relations/Listing Listing Department Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Plot No. C/1, G Block, Floor 25, P.J. Towers, Bandra – Kurla Complex, Dalal Street, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 501423 Scrip Code: SHAILY Sub: Q2 & H1 FY27 – Investor Presentation Ref: Regulation 30 of the SEBI Listing Regulations, 2015 Dear Sir, In continuation to our letter dated 22nd October 2026, regarding intimation of Earnings Call of the Company scheduled on Friday, 30th October 2026 at 04:00 p.m., IST, to discuss the operational & financial performance of the Company for the quarter and half year ended on 30th September 2026, kindly find enclosed herewith Q2 & H1 FY27 Investor Presentation of the Company. A copy of the same is also available on our website www.shaily.com. Kindly take the same on record. Thanking You. Yours truly, For Shaily Engineering Plastics Limited Harish Punwani Company Secretary & Compliance Officer M.No. A 50950 Encl: a/a Shaily Engineering Plastics Ltd. Investor Presentation October 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Shaily Engineering Plastics Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Key Performance Highlights Business Updates for Q2 FY27 Healthcare Consumer Business confirmation received for Semaglutide pens supply by the company • Two new contracts signed for IP led platforms • New product from an existing home furnishing customer Two-step Reusable Auto-Injector Pen launched for GLP-1 therapies • Increased volumes for existing product • Shaily AI TobyTM Reusable from home furnishing customer Capacity Addition Industrial • 25 Mn Pens capacity is expected to be added Business confirmation received for • Automation machines received, currently under commissioning and validation stage • 7 new products on Power Tools Abu Dhabi Facility • New knobs from an Appliance customer • Setting up of a Facility in Abu Dhabi for manufacturing Medical Devices Other Update • Expected investment of AED 130–150 million (~ Rs.350 Crores) Rating Upgrade by CARE Ratings • Strategic expansion to support global GLP-1 opportunity • Short Term Bank Facilities of Rs.35 Crs. upgraded to CARE A1+ from CARE A1 • This facility is expected to add a capacity of 75 Mn pens annually New Product Launch : Shaily AI Toby Reusable Two-step reusable auto-injector platform for GLP-1 therapies Why it matters Compared with a fully disposable auto-injector Less material Only the Syringe Pod is single-use; the driver is reused Lower energy use Less device volume to manufacture for every dose How it works Lighter shipping Smaller single-use units to transport 1 2 3 Smaller cold-chain load Single-use Syringe Retained driver Two-step injection Less device volume to keep refrigerated Holds the pre-filled The Pod attaches to a Subcutaneous delivery syringe; replaced with reusable driver kept by with needle lockout each dose the patient after use A stronger sustainability case for a weekly GLP-1 therapy taken over years Key Consolidated Financial Highlights – Q2 & H1 FY27 Revenues Gross Profit Margin EBITDA +70 bps +310 bps +24% +19% +25% +22% 319.5 600.2 59.3% 60.0% 58.4% 101.8 185.1 55.3% 256.7 503.3 81.6 152.0 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 EBITDA Margins* Profit After Tax Cash PAT# +10 bps +60 bps +20% +18% +19% +19% 31.8% 31.9% 30.2% 30.8% 61.3 109.3 75.5 137.6 51.3 92.4 63.3 115.8 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 (Rs. Cr.) #Cash PAT includes PAT & Depreciation 6 Segment Wise Revenue Breakup Revenue (Consumer) Revenue (Healthcare) Revenue (Industrial) TOTAL REVENUE Weaker Market Demand for Home Furnishings across +78% +23% +24% 2 Europe & USA Y 175.1 28.6 319.5 F -14% 23.2 256.7 98.6 134.9 115.9 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Revenue (Consumer) Revenue (Healthcare) Revenue (Industrial) TOTAL REVENUE +81% +24% +19% 7 -19% Y 286.3 317.5 51.3 600.2 F 231.4 41.3 503.3 H 175.7 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 Improved traction in the healthcare segment has been the key driver for the overall growth of the business On Consolidated Basis 7 Operational Trends +470 bps Revenue Analysis – Domestic vs. Exports 52.5% 47.8% The shift in the domestic-export mix is primarily due to the growing Healthcare business, where supplies to Indian pharma customers ultimately cater to global markets. i t( H1 FY26 H1 FY27 z i s t Q2 FY26 Q2 FY27 is +310 bps 28.3% cr 37.1% 48.2% 51.3% MA vs. 62.9% 71.7% H1 FY26 H1 FY27 Export Domestic On Consolidated Basis 8 Efficient Use of Capital RoCE RoE Fixed Asset Turnover Total Debt / Equity +530 bps +280 bps 41.1% 29.7% 2.0 0.3 26.9% 35.8% Mar-26 Sep-26* Mar-26 Sep-26* Mar-26 Sep-26* Mar-26 Sep-26 On Consolidated Basis; *On Annualized basis 9 Consolidated Profit & Loss Statement Particulars (Rs. Crs.) Q2 FY27 Q2 FY26 Y-o-Y H1 FY27 H1 FY26 Y-o-Y Revenue 319.5 256.7 24% 600.2 503.3 19% Raw Material 127.7 104.5 249.5 225.0 Employee Expenses 34.8 26.3 67.6 51.2 Other Expenses* 59.9 46.5 102.9 79.5 Other Income 4.7 2.3 5.0 4.4 EBITDA 101.8 81.7 25% 185.1 152.0 22% EBITDA Margin 31.9% 31.8% 10 bps 30.8% 30.2% 60 bps Depreciation 14.3 12.0 28.3 23.4 Finance Cost 3.0 3.9 6.3 7.8 PBT 84.5 65.8 28% 150.5 120.8 25% PBT Margin 26.5% 25.6% 90 bps 25.1% 24.0% 110 bps Tax 23.3 14.4 41.2 28.4 PAT 61.3 51.3 20% 109.3 92.4 18% [Showing first 8,000 characters — download PDF for full document]